journal article·2024-03-19

In Situ Self-Assembled Phytopolyphenol-Coordinated Intelligent Nanotherapeutics for Multipronged Management of Ferroptosis-Driven Alzheimer’s Disease

Yining Liu, Dongju Zhao, Fan Yang, Caihua Ye, Ziyao Chen, Yihan Chen, Xiaomeng Yu, Jiyao Xie, Yan Dou, Jin Chang

ACS Nano· Volume 18· Issue 11
Publisher page

Abstract

Ferroptosis is a vital driver of pathophysiological consequences of Alzheimer’s disease (AD). High-efficiency pharmacological inhibition of ferroptosis requires comprehensive coordination of diverse abnormal intracellular events, which is an urgent problem and great challenge for its application in AD treatment. Herein, a triphenylphosphonium-modified quercetin-derived smart nanomedicine (TQCN) is developed for multipronged anti-ferroptosis therapy in AD. Taking advantage of the favorable brain-targeting and mitochondria-locating properties, TQCN can efficiently chelate iron through phytopolyphenol-mediated spontaneous coordination and self-assemble into metal-phenolic nanocomplexes in situ, exerting escalating exogenous offensive effects to attenuate iron overload and its induced free radical burst. Meanwhile, the Nrf2 signaling-mediated endogenous defensive system is reconstituted to restore iron metabolism homeostasis represented by iron export and storage and enhance cytoprotective antioxidant cascades represented by lipid peroxidation detoxification. Benefiting from the multifaceted regulation of pathogenic processes triggering ferroptosis, TQCN treatment can ameliorate various neurodegenerative manifestations associated with brain iron deposition and rescue severe cognitive decline in AD mice. This work displays great promise of in situ self-assembled phytopolyphenol-coordinated intelligent nanotherapeutics as advanced candidates against ferroptosis-driven AD progression.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Ferroptosis and cancer prognosis · Trace Elements in Health · MicroRNA in disease regulation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Life Sciences, Tianjin University, Tianjin 300072, People’s Republic of China

Department of Radiology and Tianjin Key Laboratory of Functional Imaging, Tianjin Medical University General Hospital, Tianjin 300052, People’s Republic of China

Funding

Natural Science Foundation of Tianjin Municipality · National Key Clinical Specialty Discipline Construction Program of China · National Natural Science Foundation of China

References (49)

Show source-provided references
1. 10.1212/WNL.000000000001002210.1212/WNL.0000000000010022 ↗
2. 10.1016/S0140-6736(20)32205-410.1016/S0140-6736(20)32205-4 ↗
3. 10.1016/j.ccr.2016.04.01310.1016/j.ccr.2016.04.013 ↗
4. 10.1126/sciadv.ade762210.1126/sciadv.ade7622 ↗
5. 10.3389/fnins.2019.0144310.3389/fnins.2019.01443 ↗
6. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
7. 10.3390/ph1510117710.3390/ph15101177 ↗
8. 10.3389/fnagi.2022.99829210.3389/fnagi.2022.998292 ↗
9. 10.1016/j.freeradbiomed.2022.01.00210.1016/j.freeradbiomed.2022.01.002 ↗
10. 10.7150/ijbs.6971410.7150/ijbs.69714 ↗
11. 10.1007/s13238-016-0297-y10.1007/s13238-016-0297-y ↗
12. 10.1021/acsami.2c1050610.1021/acsami.2c10506 ↗
13. Mobarra N. · Int. J. Hematol. Oncol. Ste. Cell Res. · 2016 · 10 · 239
14. 10.1002/14651858.CD004450.pub310.1002/14651858.CD004450.pub3 ↗
15. 10.1186/s12951-021-01059-010.1186/s12951-021-01059-0 ↗
16. 10.1039/b705136k10.1039/b705136k ↗
17. 10.1016/j.phymed.2021.15389410.1016/j.phymed.2021.153894 ↗
18. 10.1016/j.ejphar.2019.17288510.1016/j.ejphar.2019.172885 ↗
19. 10.1021/acsnano.9b0645310.1021/acsnano.9b06453 ↗
20. 10.1016/j.cej.2023.14269710.1016/j.cej.2023.142697 ↗
21. 10.1016/S0169-409X(01)00125-910.1016/S0169-409X(01)00125-9 ↗
22. 10.1021/ja01190a02410.1021/ja01190a024 ↗
23. 10.1007/BF0059786810.1007/BF00597868 ↗
24. 10.1016/j.biomaterials.2020.11984410.1016/j.biomaterials.2020.119844 ↗
25. 10.1016/j.bioactmat.2020.08.01710.1016/j.bioactmat.2020.08.017 ↗
26. 10.1016/j.apsusc.2007.09.06310.1016/j.apsusc.2007.09.063 ↗
27. 10.1002/adma.20221099410.1002/adma.202210994 ↗
28. Ezzati Nazhad Dolatabadi J. · Adv. Pharm. Bull. · 2014 · 4 · 101
29. 10.1039/C6CC08607A10.1039/C6CC08607A ↗
30. 10.1016/j.molcel.2018.10.04210.1016/j.molcel.2018.10.042 ↗
31. 10.1007/s00109-009-0565-x10.1007/s00109-009-0565-x ↗
32. 10.1002/alz.05848910.1002/alz.058489 ↗
33. 10.1002/advs.20200455510.1002/advs.202004555 ↗
34. 10.1021/acsnano.1c0370710.1021/acsnano.1c03707 ↗
35. 10.1111/jpi.1242210.1111/jpi.12422 ↗
36. 10.1002/adma.20220710710.1002/adma.202207107 ↗
37. 10.1016/j.cell.2017.09.02110.1016/j.cell.2017.09.021 ↗
38. 10.1016/j.freeradbiomed.2023.06.01910.1016/j.freeradbiomed.2023.06.019 ↗
39. 10.1155/2022/429520810.1155/2022/4295208 ↗
40. 10.1080/1071576000030126110.1080/10715760000301261 ↗
41. 10.1016/j.apsb.2020.11.02310.1016/j.apsb.2020.11.023 ↗
42. 10.1007/s13346-021-00940-710.1007/s13346-021-00940-7 ↗
43. 10.1021/acsnano.1c0800810.1021/acsnano.1c08008 ↗
44. 10.1038/s41418-020-00685-910.1038/s41418-020-00685-9 ↗
45. 10.1016/j.freeradbiomed.2020.07.01210.1016/j.freeradbiomed.2020.07.012 ↗
46. 10.1002/advs.20220459610.1002/advs.202204596 ↗
47. 10.1148/radiol.202120307110.1148/radiol.2021203071 ↗
48. 10.1016/j.neuroimage.2009.05.00610.1016/j.neuroimage.2009.05.006 ↗
49. 10.18632/aging.10138410.18632/aging.101384 ↗